06826.HK
Shanghai Haohai Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 15.63
−2.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3B | 2.4B | 2.7B | 2.6B | 2.1B |
| Cost of Revenue | 817.3M | 756.8M | 810.9M | 781.4M | 656.5M |
| Gross Profit | 1.5B | 1.7B | 1.9B | 1.9B | 1.4B |
| Operating Expenses | |||||
| R&D Expense | 187.6M | 220.0M | 260.8M | 220.1M | 182.2M |
| SG&A Expense | 1.1B | 1.2B | 1.2B | 1.2B | 1.1B |
| General & Admin Expense | 85.4M | 426.9M | 447.0M | 422.3M | 405.3M |
| Selling & Marketing Expense | 161.9M | 814.8M | 780.9M | 814.5M | 679.5M |
| Other Expenses | 560.8M | — | (66.0M) | (41.8M) | 24.1M |
| Total Operating Expenses | 1.5B | 1.5B | 1.4B | 1.4B | 1.3B |
| Cost and Expenses | 2.3B | 2.2B | 2.3B | 2.3B | 1.9B |
| Operating Income (EBIT) | (46.8M) | 221.6M | 347.9M | 438.4M | 155.8M |
| Non-Operating | |||||
| Interest Income | 63.5M | 74.9M | 74.0M | 77.7M | 87.9M |
| Interest Expense | 17.7M | 18.4M | 18.1M | 7.3M | 7.6M |
| Net Interest Income | 45.8M | 56.5M | 55.9M | 70.4M | 80.3M |
| Other Non-Op Income/Expense | 128.8M | 17.6M | 118.2M | 69.9M | 79.9M |
| Non-Operating Income (excl Interest) | — | — | (24.1M) | (77.2M) | (23.2M) |
| EBT (Pre-Tax Income) | 81.9M | 239.2M | 466.1M | 508.3M | 235.7M |
| Income Tax Expense | 7.2M | 30.1M | 89.9M | 96.0M | 45.4M |
| Bottom Line | |||||
| Net Income | 102.0M | 244.5M | 420.4M | 416.1M | 180.5M |
| Earnings from Cont. Ops | 74.7M | 202.9M | 376.2M | 412.3M | 190.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 102.0M | 244.5M | 420.2M | 416.1M | 180.5M |
| Per Share | |||||
| Basic EPS | HK$0.44 | HK$1.08 | HK$1.80 | HK$2.44 | HK$1.04 |
| Diluted EPS | HK$0.44 | HK$1.08 | HK$1.80 | HK$2.44 | HK$1.04 |
| Revenue Per Share | HK$10.09 | HK$10.53 | HK$11.50 | HK$15.43 | HK$12.12 |
| Shares | |||||
| Basic Shares Outstanding | 224.8M | 232.4M | 233.1M | 170.8M | 173.5M |
| Diluted Shares Outstanding | 224.8M | 232.4M | 233.1M | 170.8M | 173.6M |
| Profitability Metrics | |||||
| EBITDA | 120.6M | 446.0M | 577.3M | 713.4M | 447.5M |
| D&A | 164.5M | 206.8M | 205.2M | 197.9M | 204.2M |
| EBIT | (43.9M) | 239.2M | 372.0M | 515.6M | 243.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026